- Advertise
- Contact Us
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Practical Cardiology. All rights reserved.
Heart Failure
The Practical Cardiology(TM) Heart Failure clinical resource center is an information hub for the latest in heart failure and heart failure management. With a focus on heart failure with reduced and preserved ejection fraction (HFrEF and HFpEF) this page features content including articles, videos, podcasts, and clinician-authored columns on FDA approvals, studies, guideline updates, and more.
LIFE Trial: Sacubitril/Valsartan No Better than Valsartan in Advanced Heart Failure
November 04, 2021
Results of the LIFE trial suggest sacubitril/valsartan failed to outperform valsartan alone for multiple end points of interest, including reductions of NT-proBNP.
Guideline-Directed Therapy for HFpEF and the Use of Spironolactone and Sacubitril/Valsartan
November 02, 2021
A panel of experts converse about the impact of guideline-directed therapy, as well as the use of spironolactone and sacubitril/valsartan for patients with heart failure with preserved ejection fraction.
Newer and Developing Therapies for Treating HFrEF
November 01, 2021
Javed Butler, MD, discusses some new, as well as developing, therapies used to treat HFrEF.
Using SGLT2 Inhibitors for Quadruple Therapy in the Management of HFrEF
November 01, 2021
Dr Javed Butler closes out the quadruple therapy discussion with analyzing the use of SGLT2 inhibitors for patients with heart failure with reduced ejection fraction.
Cardiology Month in Review: October 2021
October 30, 2021
October's cardiology month in review features a pair of historic guidelines, questions around the risk of arrhythmia associated with omega-3 supplements, myocarditis and Pfizer vaccines, and more.
Using ARNIs for Quadruple Therapy in the Management of HFrEF
October 29, 2021
Nasrien Ibrahim, MD, considers using angiotensin receptor-neprilysin inhibitors in quadruple therapy when treating patients with heart failure with reduced ejection fraction.
Using MRAs for Quadruple Therapy in the Management of HFrEF
October 29, 2021
Javed Butler, MD, discusses the class of mineralocorticoid receptor antagonists used within quadruple therapy for patients with heart failure with reduced ejection fraction.
Using Beta Blockers for Quadruple Therapy in the Management of HFrEF
October 28, 2021
Gregg Fonarow, MD, relays pertinent information concerning the use of beta blockers in quadruple therapy in the management of heart failure with reduced ejection fraction.
Deciding on an Initial Treatment for Heart Failure
October 28, 2021
Dr Javed Butler provides examples of the considered factors when deciding on an initial treatment for patients with heart failure.
PCPs’ and Cardiologists’ Roles in Heart Failure Prevention
October 27, 2021
Dr Nasrien Ibrahim explains when primary care physicians and cardiologists should make referrals to help patients with heart failure in order to prevent advanced disease.